Longevica Therapeutics Appoints Ex-Genentech Veteran Dr. Prasun Mishra as CEO to Advance World's Largest Mammalian Longevity Study Toward the Clinic
核心洞察
Longevica Therapeutics (搜索) has appointed Dr. Prasun Mishra, a former Genentech/Roche and NIH executive, as CEO to transition its longevity discovery platform into clinical development.
The appointment follows completion of a four-year, $13 million in vivo screen at The Jackson Laboratory that tested 1,033 small-molecule compounds across more than 16,000 mice over their natural lifespans.
Deep mechanistic analysis of the dataset identified two previously uncharacterized biological mechanisms tied to mammalian lifespan extension, laying the foundation for IND-enabling studies.
Longevica Therapeutics (搜索), a preclinical biotechnology company pioneering target discovery from full-lifespan mammalian geroscience, has appointed biopharmaceutical executive Dr. Prasun Mishra as Chief Executive Officer and member of its Board of Directors. The appointment, announced August 18, 2026, marks the company's strategic transition from foundational discovery to systematic drug development, accelerating the translation of its proprietary mammalian longevity dataset into clinical pipeline candidates.
Dr. Mishra brings more than two decades of biopharmaceutical R&D, translational medicine, and strategic corporate leadership to Longevica. His career spans executive and scientific leadership roles at Genentech, Roche, the National Institutes of Health (NIH), the National Cancer Institute (NCI), the University of California, San Francisco (UCSF), and Rutgers University. Over his career, Dr. Mishra has spearheaded more than 30 therapeutic research programs, advancing 12 distinct candidate molecules into clinical trials and guiding four therapeutics through global regulatory approvals.
A Landmark Full-Lifespan Mammalian Screen
Dr. Mishra's appointment follows the completion of Longevica's landmark four-year, $13 million in vivo mammalian screening program conducted at The Jackson Laboratory. The program systematically evaluated 1,033 small-molecule compounds across more than 16,000 mouse subjects over their natural lifespans, generating a proprietary dataset that Longevica characterizes as the world's largest mammalian longevity screening program of its kind and one of the most rigorous empirical datasets in translational aging science.
The screen's design distinguishes it from much of the prior work in the field. Rather than relying on short-lived model organisms such as C. elegans and Drosophila, cellular assays, or computational modeling, Longevica deployed an unbiased screening architecture across 1,033 structurally diverse chemical entities, tracking mouse cohorts from maturity through natural death. This approach experimentally mapped compound exposure directly to lifespan outcomes across full physiological life cycles.
Reverse-Engineering Lifespan Phenotypes into Druggable Pathways
Deep mechanistic analysis of the Jackson Laboratory dataset has already revealed two previously uncharacterized candidate biological mechanisms governing mammalian lifespan extension. These insights enable Longevica to reverse-engineer observed phenotypic lifespan extensions into precise, druggable biological pathways, transforming observational longevity data into small-molecule drug development programs.
By integrating the proprietary screening dataset with predictive AI models and computational chemistry, Longevica is training machine learning algorithms on empirical mammalian longevity outcomes rather than unverified public literature or isolated cell-line data. The company reports that this data-driven engine accelerates target identification and validation, mechanism mapping, and lead optimization for novel therapeutic entities.
Leadership to Drive Preclinical Execution
Longevica's founder and chairman, Alexander Chikunov, framed the hire in the context of an industry-wide challenge. "Over the past decade, the longevity sector has faced a fundamental translational validation challenge. The industry frequently attempted to build clinical pipelines on retrospective data mining, short-lived lower organisms, or reductionist cell assays that fail to reflect mammalian physiology," Chikunov said. "Longevica chose to address that challenge at the source by investing four years and $13 million to build an empirical, full-lifespan dataset at The Jackson Laboratory."
Dr. Mishra articulated the company's strategic focus. "The central challenge in geroscience is no longer simply establishing that aging biology is modifiable, but determining which mammalian mechanisms can be translated into disease-modifying prescription therapeutics," he said. "While much of the field remains constrained by academic observation or pure computational modeling, Longevica generated hard, full-lifespan in vivo data across more than 1,000 small molecules in a mammalian system."
Three-Pillar Growth Strategy
Under Dr. Mishra's leadership, Longevica is executing a structured, three-pillar growth plan. The first pillar involves advancing lead small-molecule candidates targeting newly identified longevity mechanisms into formal IND-enabling studies, initially prioritizing high-unmet-need, age-related metabolic dysfunction (搜索) and systemic fibrotic disorders (搜索). The second pillar expands the company's proprietary computational drug discovery engine by integrating machine learning models with the full-lifespan Jackson Laboratory dataset. The third pillar pursues co-development partnerships with global pharmaceutical companies for human prescription indications.
A Dual-Front Commercial Model
In addition to its core human prescription therapeutic pipeline, Longevica's platform provides a direct translational bridge into pet health and veterinary medicine. Because companion animals experience age-related pathologies similar to humans over compressed lifespans, veterinary therapeutics offer a rapid clinical validation pathway and near-term commercial execution alongside long-horizon human biopharma development. Guiding this multi-front translational strategy is an advisory board comprising leaders from Harvard University, UC Berkeley, Rutgers University, and life sciences venture capital firms.